Cite
HARVARD Citation
Sullivan, R. et al. (n.d.). 130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor. Immuno-oncology technology. p. . [Online].